0	0	2000-09-23	CD	O	O	B-Num
0	1	00	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	55	CD	O	B-NP	I-Num
0	4	EDITORIAL	NNP	O	I-NP	O
0	5	:	:	O	O	O
0	6	APPROVAL	NNP	O	B-NP	O
0	7	FOR	IN	O	B-PP	O
0	8	RU-486	NNP	O	B-NP	O

1	0	The	DT	O	B-NP	O
1	1	New	NNP	O	I-NP	B-OrgCorp
1	2	York	NNP	O	I-NP	I-OrgCorp
1	3	Times	NNP	O	I-NP	I-OrgCorp
1	4	said	VBD	O	B-VP	O
1	5	in	IN	O	B-PP	O
1	6	an	DT	O	B-NP	O
1	7	editorial	NN	O	I-NP	O
1	8	on	IN	O	B-PP	O
1	9	Saturday	NNP	O	B-NP	B-Date
1	10	COMMA	COMMA	O	O	O
1	11	Sept.	NNP	O	B-NP	B-Date
1	12	23	CD	O	I-NP	I-Date
1	13	:	:	O	O	O

2	0	The	DT	O	B-NP	O
2	1	Food	NNP	O	I-NP	B-Org
2	2	and	CC	O	I-NP	I-Org
2	3	Drug	NNP	O	I-NP	I-Org
2	4	Administration	NNP	O	I-NP	I-Org
2	5	is	VBZ	O	B-VP	O
2	6	expected	VBN	O	I-VP	O
2	7	to	TO	O	I-VP	O
2	8	announce	VB	O	I-VP	O
2	9	a	DT	O	B-NP	O
2	10	decision	NN	O	I-NP	O
2	11	next	JJ	O	B-NP	O
2	12	week	NN	O	I-NP	O
2	13	on	IN	O	B-PP	O
2	14	the	DT	O	B-NP	O
2	15	fate	NN	O	I-NP	O
2	16	of	IN	O	B-PP	O
2	17	RU-486	NNP	O	B-NP	B-Org
2	18	COMMA	COMMA	O	O	O
2	19	the	DT	O	B-NP	O
2	20	abortion	NN	O	I-NP	B-Medical
2	21	pill	NN	O	I-NP	O
2	22	that	WDT	O	B-NP	O
2	23	can	MD	O	B-VP	O
2	24	offer	VB	O	I-VP	O
2	25	women	NNS	O	B-NP	O
2	26	a	DT	O	B-NP	O
2	27	safe	JJ	O	I-NP	O
2	28	COMMA	COMMA	O	I-NP	O
2	29	non-invasive	JJ	O	I-NP	O
2	30	alternative	NN	O	I-NP	B-Medical
2	31	to	TO	O	B-PP	O
2	32	surgical	JJ	O	B-NP	B-Medical
2	33	abortion	NN	O	I-NP	B-Medical
2	34	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	agency	NN	O	I-NP	B-OrgCorp
3	2	faces	VBZ	O	B-VP	O
3	3	a	DT	O	B-NP	O
3	4	Sept.	NNP	O	I-NP	B-Date
3	5	30	CD	O	I-NP	I-Date
3	6	deadline	NN	O	I-NP	O
3	7	on	IN	O	B-PP	O
3	8	whether	IN	O	O	O
3	9	to	TO	O	B-VP	O
3	10	give	VB	O	I-VP	O
3	11	final	JJ	O	B-NP	O
3	12	marketing	NN	O	I-NP	O
3	13	approval	NN	O	I-NP	O
3	14	for	IN	O	B-PP	O
3	15	the	DT	O	B-NP	O
3	16	drug	NN	O	I-NP	B-Medical
3	17	COMMA	COMMA	O	O	O
3	18	call	VBP	O	B-VP	O
3	19	for	IN	O	B-PP	O
3	20	a	DT	O	B-NP	O
3	21	delay	NN	O	I-NP	O
3	22	of	IN	O	B-PP	O
3	23	action	NN	O	B-NP	O
3	24	or	CC	O	O	O
3	25	deny	VBP	O	B-VP	O
3	26	approval	NN	O	B-NP	O
3	27	.	.	O	O	O

4	0	RU-486	NNP	O	B-NP	O
4	1	would	MD	O	B-VP	O
4	2	be	VB	O	I-VP	O
4	3	a	DT	O	B-NP	O
4	4	crucial	JJ	O	I-NP	O
4	5	breakthrough	NN	O	I-NP	O
4	6	in	IN	O	B-PP	O
4	7	abortion	NN	O	B-NP	B-Medical
4	8	access	NN	O	I-NP	O
4	9	in	IN	O	B-PP	O
4	10	this	DT	O	B-NP	O
4	11	country	NN	O	I-NP	O
4	12	because	IN	O	O	O
4	13	it	PRP	O	B-NP	O
4	14	can	MD	O	B-VP	O
4	15	be	VB	O	I-VP	O
4	16	administered	VBN	O	I-VP	O
4	17	by	IN	O	B-PP	O
4	18	primary	JJ	O	B-NP	O
4	19	care	NN	O	I-NP	O
4	20	doctors	NNS	O	I-NP	B-ProfTitle
4	21	in	IN	O	B-PP	O
4	22	communities	NNS	O	B-NP	O
4	23	where	WRB	O	O	O
4	24	surgical	JJ	O	B-NP	B-Medical
4	25	abortion	NN	O	I-NP	B-Medical
4	26	services	NNS	O	I-NP	O
4	27	are	VBP	O	B-VP	O
4	28	nonexistent	JJ	O	O	O
4	29	.	.	O	O	O

5	0	Patients	NNS	O	B-NP	O
5	1	with	IN	O	B-PP	O
5	2	RU-486	NNP	O	B-NP	O
5	3	prescriptions	NNS	O	I-NP	O
5	4	would	MD	O	B-VP	O
5	5	no	RB	O	I-VP	O
5	6	longer	RB	O	I-VP	O
5	7	need	VB	O	I-VP	O
5	8	to	TO	O	I-VP	O
5	9	travel	VB	O	I-VP	O
5	10	to	TO	O	B-PP	O
5	11	clinics	NNS	O	B-NP	O
5	12	that	WDT	O	B-NP	O
5	13	are	VBP	O	B-VP	O
5	14	targets	NNS	O	B-NP	O
5	15	of	IN	O	B-PP	O
5	16	abortion	NN	O	B-NP	B-Medical
5	17	protests	NNS	O	I-NP	O
5	18	.	.	O	O	O

6	0	Not	RB	O	O	O
6	1	surprisingly	RB	O	O	O
6	2	COMMA	COMMA	O	O	O
6	3	anti-abortion	JJ	O	B-NP	O
6	4	groups	NNS	O	I-NP	B-OrgCorp
6	5	have	VBP	O	B-VP	O
6	6	vehemently	RB	O	I-VP	O
6	7	opposed	VBN	O	I-VP	O
6	8	FDA	NNP	O	O	O
6	9	approval	NN	O	O	O
6	10	.	.	O	O	O

7	0	There	EX	O	B-NP	O
7	1	is	VBZ	O	B-VP	O
7	2	overwhelming	JJ	O	B-NP	O
7	3	evidence	NN	O	I-NP	O
7	4	of	IN	O	B-PP	O
7	5	RU-486	NNP	O	B-NP	B-Org
7	6	's	POS	O	B-NP	O
7	7	safety	NN	O	I-NP	O
7	8	and	CC	O	I-NP	O
7	9	effectiveness	NN	O	I-NP	O
7	10	in	IN	O	B-PP	O
7	11	a	DT	O	B-NP	O
7	12	decade	NN	O	I-NP	O
7	13	of	IN	O	B-PP	O
7	14	use	VBP	O	B-NP	O
7	15	by	IN	O	B-PP	O
7	16	more	JJR	O	B-NP	O
7	17	than	IN	O	I-NP	O
7	18	500COMMA000	CD	O	I-NP	B-Num
7	19	women	NNS	O	I-NP	O
7	20	in	IN	O	B-PP	O
7	21	Europe	NNP	O	B-NP	B-Loc
7	22	and	CC	O	B-PP	O
7	23	in	IN	O	B-PP	O
7	24	clinical	JJ	O	B-NP	B-Medical
7	25	trials	NNS	O	I-NP	O
7	26	in	IN	O	B-PP	O
7	27	this	DT	O	B-NP	O
7	28	country	NN	O	I-NP	O
7	29	.	.	O	O	O

8	0	It	PRP	O	B-NP	O
8	1	is	VBZ	O	B-VP	O
8	2	time	NN	O	B-NP	O
8	3	the	DT	O	B-NP	O
8	4	FDA	NNP	O	I-NP	O
8	5	allowed	VBD	O	B-VP	O
8	6	women	NNS	O	B-NP	O
8	7	access	NN	O	B-NP	O
8	8	to	TO	O	B-PP	O
8	9	this	DT	O	B-NP	O
8	10	important	JJ	O	I-NP	O
8	11	medical	JJ	O	I-NP	O
8	12	option	NN	O	I-NP	O
8	13	without	IN	O	B-PP	O
8	14	unnecessary	JJ	O	B-NP	O
8	15	restrictions	NNS	O	I-NP	O
8	16	.	.	O	O	O

9	0	RU-486	NNP	O	B-NP	O
9	1	COMMA	COMMA	O	O	O
9	2	also	RB	O	B-VP	O
9	3	known	VBN	O	I-VP	O
9	4	as	IN	O	B-PP	O
9	5	mifepristone	NN	O	B-NP	O
9	6	COMMA	COMMA	O	O	O
9	7	was	VBD	O	B-VP	O
9	8	determined	VBN	O	I-VP	O
9	9	by	IN	O	B-PP	O
9	10	the	DT	O	B-NP	O
9	11	FDA	NNP	O	I-NP	B-Org
9	12	in	IN	O	B-PP	O
9	13	1996	CD	O	B-NP	B-Date
9	14	to	TO	O	B-VP	O
9	15	be	VB	O	I-VP	O
9	16	safe	JJ	O	O	O
9	17	and	CC	O	O	O
9	18	effective	JJ	O	O	O
9	19	in	IN	O	B-PP	O
9	20	terminating	VBG	O	B-VP	O
9	21	early	JJ	O	B-NP	O
9	22	pregnancies	NNS	O	I-NP	O
9	23	when	WRB	O	O	O
9	24	used	VBN	O	B-VP	O
9	25	with	IN	O	B-PP	O
9	26	another	DT	O	B-NP	O
9	27	already	RB	O	I-NP	O
9	28	approved	VBN	O	I-NP	O
9	29	drug	NN	O	I-NP	B-Medical
9	30	called	VBD	O	B-VP	O
9	31	misoprostol	NN	O	B-NP	O
9	32	.	.	O	O	O

10	0	But	CC	O	O	O
10	1	RU-486	NNP	O	B-NP	O
10	2	cannot	NN	O	I-NP	O
10	3	be	VB	O	B-VP	O
10	4	marketed	VBN	O	I-VP	O
10	5	until	IN	O	B-PP	O
10	6	the	DT	O	B-NP	O
10	7	FDA	NNP	O	I-NP	O
10	8	resolves	VBZ	O	B-VP	O
10	9	some	DT	O	B-NP	O
10	10	manufacturing	NN	O	I-NP	O
10	11	COMMA	COMMA	O	I-NP	O
10	12	labeling	NN	O	I-NP	O
10	13	and	CC	O	I-NP	O
10	14	distribution	NN	O	I-NP	O
10	15	concerns	NNS	O	I-NP	O
10	16	.	.	O	O	O

11	0	Those	DT	O	B-NP	O
11	1	issues	NNS	O	I-NP	O
11	2	are	VBP	O	B-VP	O
11	3	being	VBG	O	I-VP	O
11	4	negotiated	VBN	O	I-VP	O
11	5	between	IN	O	B-PP	O
11	6	the	DT	O	B-NP	O
11	7	agency	NN	O	I-NP	B-OrgCorp
11	8	and	CC	O	O	O
11	9	Danco	NNP	O	B-NP	O
11	10	Laboratories	NNP	O	I-NP	O
11	11	COMMA	COMMA	O	O	O
11	12	the	DT	O	B-NP	O
11	13	group	NN	O	I-NP	B-OrgCorp
11	14	that	WDT	O	B-NP	O
11	15	seeks	VBZ	O	B-VP	O
11	16	to	TO	O	I-VP	O
11	17	market	VB	O	I-VP	O
11	18	the	DT	O	B-NP	O
11	19	drug	NN	O	I-NP	B-Medical
11	20	.	.	O	O	O

12	0	Earlier	RBR	O	B-NP	O
12	1	this	DT	O	I-NP	O
12	2	year	NN	O	I-NP	O
12	3	there	EX	O	B-NP	O
12	4	was	VBD	O	B-VP	O
12	5	considerable	JJ	O	B-NP	O
12	6	concern	NN	O	I-NP	O
12	7	among	IN	O	B-PP	O
12	8	pro-choice	JJ	O	B-NP	O
12	9	groups	NNS	O	I-NP	B-OrgCorp
12	10	that	IN	O	O	O
12	11	the	DT	O	B-NP	O
12	12	FDA	NNP	O	I-NP	B-Org
12	13	would	MD	O	B-VP	O
12	14	impose	VB	O	I-VP	O
12	15	strict	JJ	O	B-NP	O
12	16	distribution	NN	O	I-NP	O
12	17	limits	NNS	O	I-NP	O
12	18	on	IN	O	B-PP	O
12	19	RU-486	NNP	O	B-NP	O
12	20	.	.	O	O	O

13	0	The	DT	O	B-NP	O
13	1	FDA	NNP	O	I-NP	B-Org
13	2	was	VBD	O	B-VP	O
13	3	said	VBD	O	I-VP	O
13	4	to	TO	O	I-VP	O
13	5	want	VB	O	I-VP	O
13	6	only	RB	O	O	O
13	7	doctors	NNS	O	B-NP	B-ProfTitle
13	8	who	WP	O	B-NP	O
13	9	can	MD	O	B-VP	O
13	10	perform	VB	O	I-VP	O
13	11	surgical	JJ	O	B-NP	B-Medical
13	12	abortions	NNS	O	I-NP	O
13	13	to	TO	O	B-VP	O
13	14	prescribe	VB	O	I-VP	O
13	15	RU-486	NNP	O	B-NP	O
13	16	.	.	O	O	O

14	0	Another	DT	O	B-NP	O
14	1	proposal	NN	O	I-NP	O
14	2	was	VBD	O	B-VP	O
14	3	to	TO	O	B-VP	O
14	4	require	VB	O	I-VP	O
14	5	prescribing	VBG	O	O	O
14	6	doctors	NNS	O	B-NP	B-ProfTitle
14	7	to	TO	O	O	O
14	8	have	VB	O	O	O
14	9	admitting	VBG	O	B-NP	O
14	10	privileges	NNS	O	I-NP	O
14	11	at	IN	O	B-PP	O
14	12	hospitals	NNS	O	B-NP	O
14	13	within	IN	O	B-PP	O
14	14	an	DT	O	B-NP	O
14	15	hour	NN	O	I-NP	O
14	16	of	IN	O	B-PP	O
14	17	their	PP$	O	B-NP	O
14	18	offices	NNS	O	I-NP	O
14	19	.	.	O	O	O

15	0	Such	JJ	O	B-NP	O
15	1	restrictions	NNS	O	I-NP	O
15	2	would	MD	O	B-VP	O
15	3	greatly	RB	O	I-VP	O
15	4	limit	VB	O	I-VP	O
15	5	use	NN	O	B-NP	O
15	6	of	IN	O	B-PP	O
15	7	the	DT	O	B-NP	O
15	8	drug	NN	O	I-NP	B-Medical
15	9	COMMA	COMMA	O	O	O
15	10	and	CC	O	O	O
15	11	do	VBP	O	B-VP	O
15	12	not	RB	O	I-VP	O
15	13	seem	VB	O	I-VP	O
15	14	medically	RB	O	O	O
15	15	necessary	JJ	O	O	O
15	16	.	.	O	O	O

16	0	The	DT	O	B-NP	O
16	1	FDA	NNP	O	I-NP	B-Org
16	2	should	MD	O	B-VP	O
16	3	approve	VB	O	I-VP	O
16	4	RU-486	NNP	O	B-NP	O
16	5	promptly	RB	O	O	O
16	6	without	IN	O	B-PP	O
16	7	restrictions	NNS	O	B-NP	O
16	8	that	IN	O	B-NP	O
16	9	undermine	VBP	O	B-VP	O
16	10	broad	JJ	O	B-NP	O
16	11	access	NN	O	I-NP	O
16	12	.	.	O	O	O
